0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover953.22%IV-29.45%PremiumJan 17, 2025Expiry Date0.91Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.2260Delta0.0543Gamma1.14Leverage Ratio-0.0666Theta-0.0010Rho-0.26Eff Leverage0.0017Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet